Alkem Laboratories Introduces Renocia Nutritional Kit for Hair Growth
Filing Summary
Alkem Laboratories Ltd. has launched the Renocia cyclical therapy kit, a nutritional supplements regimen designed to support hair growth. The kit includes vitamins, minerals, and amino acids, structured for weekly intake to enhance nutrient absorption. It is available in separate formulations for men and women, using only vegetarian-sourced ingredients. This product is part of Alkem’s expanding dermatology portfolio, which includes various hair care products under the Renocia brand. The kit is a prescription product, available in a four-week wallet pack for consumer convenience.
On January 8, 2026, Alkem Laboratories Ltd. announced the launch of the Renocia cyclical therapy kit, a nutritional supplements regimen aimed at supporting hair growth. The kit is designed as a weekly nutritional supplementation protocol, incorporating vitamins, minerals, and amino acids. This structured approach is intended to facilitate better nutrient absorption and utilization.
The Renocia cyclical therapy kit is formulated with separate versions for men and women, addressing specific nutritional needs. The supplements are made exclusively from vegetarian-sourced ingredients. The product is available in a wallet pack, containing supplements for four weeks, with clear instructions on daily intake. This product is available by prescription only.
Alkem has a growing portfolio in the dermatology segment, which includes skin and hair care products. Under the Renocia brand, the company offers various hair care products, including revitalizing shampoo, conditioner, serum, and oral supplements. The launch of the cyclical therapy kit is part of Alkem’s strategy to expand its offerings in the hair care market.
Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a 50-year legacy in providing high-quality medicines. It holds a significant position in the Indian market, particularly in anti-infectives, gastrointestinal, and pain management drugs. The company is also expanding its portfolio in chronic therapies, including dermatology. Alkem operates 18 manufacturing facilities and R&D centers in India and the US, focusing on generic formulations, active pharmaceutical ingredients, and biosimilars. The company maintains a presence in the US, Latin America, Australia, and several Asian countries.